Halozyme Therapeutics has patented modified PH20 hyaluronidase polypeptides with increased stability and activity. The patent covers compositions, formulations, and uses of these modified polypeptides. GlobalData’s report on Halozyme Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Halozyme Therapeutics, was a key innovation area identified from patents. Halozyme Therapeutics's grant share as of May 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Modified ph20 hyaluronidase polypeptides with increased stability/activity
A recently granted patent (Publication Number: US11952600B2) discloses a modified PH20 polypeptide with specific amino acid sequences and modifications. The modified polypeptide, as described in the claims, includes variations at position 320 and exhibits enhanced hyaluronidase activity compared to the original sequence. The patent covers various aspects of the modified PH20 polypeptide, including its solubility, glycosylation, and potential therapeutic applications. Additionally, the patent extends to nucleic acids encoding the modified polypeptide, recombinant expression vectors, host cells, and pharmaceutical compositions containing the modified PH20 polypeptide along with therapeutically active agents.
Furthermore, the patent details methods for administering the pharmaceutical composition, particularly through subcutaneous administration, and for the manufacture of the modified PH20 polypeptide. The manufacturing process involves preparing a plasmid DNA containing the cDNA encoding the protein, transfecting it into a host cell, culturing the cell for protein expression, and harvesting the protein. The patent emphasizes the specific amino acid sequences, modifications, and hyaluronidase activity of the modified PH20 polypeptide, highlighting its potential in various therapeutic applications and manufacturing processes.
To know more about GlobalData’s detailed insights on Halozyme Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
